Core Viewpoint - Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is launching an IPO with a total offering of 18.321 million H-shares, aiming for a listing on the Hong Kong Stock Exchange on December 23, 2025, with ICBC International as the sole sponsor [2][3]. Offering Details - The IPO will consist of 18.321 million H-shares, with 1.8321 million shares available for reallocation and 16.4889 million shares for international offering [3]. - The maximum offering price is set at HKD 32.00 per share, with additional fees including a 1% brokerage commission and various transaction fees [3]. - The offering period is from December 15 to December 18, 2025, and the expected net proceeds are approximately HKD 4.96 billion [4][5]. Use of Proceeds - Approximately 35% of the net proceeds will be allocated to the development of the core product HX009, while 33% will be used for the main products HX301 and HX044 [5]. - Additional allocations include 17% for other important product developments, 5% for commercialization and business development activities, and 10% for working capital and general corporate purposes [5]. Shareholder Structure - The major shareholders include Dr. Zhang Faming with 40.60% and other entities holding significant stakes, resulting in a total of 55.89% ownership by major shareholders [7]. - The public offering accounts for 13.45% of the total shares [4]. Company Overview - Hanx Biopharmaceuticals focuses on discovering, developing, and commercializing innovative therapies for cancer and autoimmune diseases, with a pipeline of 10 drug candidates [7]. - The company has developed core products including HX009, a PD-1/SIRPα dual-function antibody fusion protein, and is advancing several candidates in clinical and preclinical stages [7].
翰思艾泰-B(03378)招股，12月23日香港上市，工银国际独家保荐